Long-term octreotide treatment prevents
β
C C Sieber; F Lee; R J Groszmann
π
Article
π
1996
π
John Wiley and Sons
π
English
β 210 KB
Chronically portal-hypertensive rats show in vitro vascular hyporeactivity in large part mediated by the endothelium-derived vasodilator nitric oxide. We tested whether long-term octreotide treatment (15 micrograms/kg subcutaneously in 5% D/W, 8-hourly) corrects the in vitro vascular hyporeactivity.